Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $924,754.17 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 154,383 shares of the business’s stock in a transaction dated Thursday, October 23rd. The shares were sold at an average price of $5.99, for a total value of $924,754.17. Following the completion of the transaction, the insider owned 14,711,635 shares in the company, valued at $88,122,693.65. This trade represents a 1.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total value of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total value of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.20, for a total value of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total value of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.07, for a total value of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total value of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total transaction of $420,803.95.

Vir Biotechnology Trading Up 3.5%

NASDAQ VIR opened at $5.98 on Monday. The company has a fifty day simple moving average of $5.32 and a 200 day simple moving average of $5.29. The company has a market cap of $830.74 million, a P/E ratio of -1.50 and a beta of 1.27. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.38 million. During the same quarter in the previous year, the company earned ($1.02) EPS. Vir Biotechnology’s revenue for the quarter was down 60.5% compared to the same quarter last year. Equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on VIR shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Evercore ISI started coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 target price for the company. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and increased their target price for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Finally, Raymond James Financial initiated coverage on Vir Biotechnology in a research report on Friday, July 11th. They issued an “outperform” rating for the company. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $17.30.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology in the 2nd quarter worth approximately $35,000. GAMMA Investing LLC lifted its position in shares of Vir Biotechnology by 524.3% during the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after buying an additional 5,972 shares during the period. Apollon Wealth Management LLC bought a new position in shares of Vir Biotechnology during the 2nd quarter worth approximately $50,000. PNC Financial Services Group Inc. lifted its position in shares of Vir Biotechnology by 26.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after buying an additional 2,171 shares during the period. Finally, FORA Capital LLC bought a new position in shares of Vir Biotechnology during the 1st quarter worth approximately $70,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).